A urine free light chains test looks for kappa (κ) and lambda (λ) immunoglobulin light chains that pass from the blood into urine. An excess of one light-chain type can occur when a clone of plasma cells produces a monoclonal protein, as in multiple myeloma, light-chain myeloma, AL amyloidosis, or another monoclonal gammopathy. Monoclonal free light chains found in urine are traditionally called Bence Jones proteins.
Urine light-chain testing is not interpreted by one universal normal range. Results depend on whether the laboratory uses a spot urine or 24-hour collection, the assay method, urine concentration, kidney function, and whether electrophoresis or immunofixation confirms monoclonality. Modern evaluation usually relies heavily on serum free light chains, serum protein electrophoresis, and serum immunofixation, with urine protein electrophoresis and urine immunofixation retained for specific diagnostic, renal, and response-assessment situations. Very high monoclonal light-chain production can damage the kidneys and may require urgent hematology evaluation, especially when kidney function is worsening.
- What it measures: free kappa and lambda light chains excreted in urine; a monoclonal excess may represent Bence Jones protein.
- Abnormal result: excess of one light-chain type suggests a monoclonal plasma-cell process but does not by itself diagnose multiple myeloma.
- Kidney risk: large amounts of circulating monoclonal light chains can cause cast nephropathy and other forms of monoclonal protein–related kidney injury.
- Best companion tests: serum free light chains, SPEP, serum immunofixation, UPEP, urine immunofixation, blood counts, calcium, and kidney-function tests.
- No universal urine range: interpretation depends on the laboratory method, collection type, urine concentration, and kidney handling of light chains.
Table of Contents
- What free light chains are
- Why urine free light chains are tested
- Bence Jones protein and monoclonal light chains
- How to interpret urine free light chain results
- Free light chains and kidney risk
- Urine versus serum free light chain testing
- What happens after an abnormal result
What free light chains are
Antibodies, also called immunoglobulins, are built from heavy chains and light chains. Every intact immunoglobulin contains either kappa or lambda light chains. Plasma cells normally make a small excess of light chains that are not attached to heavy chains; these are called free light chains (FLCs).
Free light chains are small enough to pass through the kidney’s glomerular filter. Under normal conditions, most filtered light chains are reabsorbed and broken down by the proximal tubules, so only small amounts reach the final urine. When plasma cells produce huge quantities of one monoclonal light chain, the kidney’s reabsorptive capacity can be overwhelmed and the abnormal protein appears in urine.
A monoclonal plasma-cell clone usually makes predominantly one light-chain type. For example, a kappa-producing myeloma may cause a large rise in serum kappa FLC with excess monoclonal kappa in urine. The same principle applies to lambda-producing disease.
This differs from a general urine protein test. Albumin is the dominant protein in many kidney diseases, while monoclonal free light chains are a different class of protein. A routine dipstick is relatively insensitive to light chains because it is designed mainly to detect albumin. That is why a patient can have clinically important Bence Jones proteinuria despite a urine dipstick that does not look dramatically positive.
Related tests answer different questions. Urine immunofixation identifies whether a urinary protein is monoclonal and whether it is kappa or lambda. Urine protein electrophoresis (UPEP) separates and can quantify a monoclonal band in a timed collection. Serum testing often detects the abnormal light chain earlier and more sensitively.
Why urine free light chains are tested
Urine light-chain testing may be ordered when a clinician suspects a plasma-cell or monoclonal protein disorder, or when such a disorder is already known and needs characterization or monitoring.
Common reasons include:
- unexplained anemia, bone pain, lytic bone lesions, or recurrent fractures;
- unexplained kidney impairment, especially with a low albumin fraction of total urine protein;
- high calcium without another clear cause;
- a monoclonal protein found on serum testing;
- an abnormal serum free light chain result;
- suspected multiple myeloma, light-chain myeloma, AL amyloidosis, or monoclonal gammopathy of renal significance;
- measurement of 24-hour monoclonal protein in a patient whose disease produces a measurable urinary M protein.
Urine testing is often part of a broader myeloma workup rather than a stand-alone tumor marker. A typical evaluation also includes complete blood count, creatinine and estimated GFR, calcium, serum protein electrophoresis, serum immunofixation, serum free light chains, and whole-body imaging when clinically indicated. Bone marrow examination is required when the laboratory and clinical picture suggests a plasma-cell neoplasm.
A urine FLC measurement can also be useful when kidney involvement is suspected because it provides direct evidence that free light chains are reaching the urine. However, the amount excreted is affected by kidney filtration and tubular reabsorption, so urine concentration is not a simple measure of how much the tumor is producing.
Bence Jones protein and monoclonal light chains
Bence Jones protein is the traditional name for monoclonal immunoglobulin free light chains in urine. It is not a separate protein from kappa or lambda light chains. The clinically important feature is monoclonality: one plasma-cell clone is making a large amount of one light-chain type.
A quantitative urine free light chain assay can show that kappa or lambda is increased, but concentration alone does not always prove that the protein is monoclonal. Polyclonal immune activation and kidney disease can alter both light-chain types. Urine immunofixation is designed to demonstrate a discrete monoclonal light-chain pattern and is therefore important when the central question is whether Bence Jones protein is present.
This is why the phrases “high urine kappa,” “Bence Jones positive,” and “multiple myeloma” are not interchangeable. A high kappa measurement needs to be interpreted alongside lambda, serum FLC values and ratio, electrophoresis, immunofixation, kidney function, and the clinical picture.
Historically, heating tests were used to identify Bence Jones proteins because of their unusual precipitation behavior. Modern laboratories use electrophoretic and immunochemical techniques instead. These methods are far more specific and can identify the light-chain type.
Spot urine versus 24-hour urine
A spot sample is easier to collect and can be useful for qualitative or ratio-based information, but urine concentration changes throughout the day with hydration. A 24-hour collection can measure total monoclonal protein excretion per day and remains important in selected myeloma and kidney evaluations.
For a timed collection, every void during the 24-hour period must be saved. Missing urine makes daily protein excretion appear lower than it truly is. If a collection is clearly incomplete, repeating it is usually more useful than overinterpreting the number.
How to interpret urine free light chain results
There is no single urine free light chain value that diagnoses myeloma. Interpretation starts with the test type and the laboratory’s own reference information.
A normal or low urine FLC result does not completely exclude a monoclonal gammopathy. Serum free light chains are often more sensitive because the kidneys may reabsorb large amounts before light chains become readily detectable in urine. Reduced filtration can also alter excretion.
An increase in both kappa and lambda can occur with reduced kidney function, inflammation, or polyclonal immune activation. That pattern is less specific for a clonal plasma-cell disorder than a clear monoclonal pattern.
A predominant elevation of one light-chain type raises more concern for monoclonal production, particularly if serum testing shows the same involved light chain and immunofixation confirms a monoclonal band.
A positive urine immunofixation for free kappa or free lambda provides stronger evidence of Bence Jones protein than an isolated quantitative concentration. It still does not tell whether the underlying diagnosis is MGUS, smoldering myeloma, active multiple myeloma, AL amyloidosis, or another B-cell/plasma-cell disorder.
| Finding | Possible meaning | What usually clarifies it |
|---|---|---|
| Both kappa and lambda increased | Reduced renal clearance or polyclonal production | Serum FLC ratio, kidney function, immunofixation |
| One light chain strongly predominant | Possible monoclonal plasma-cell production | Serum FLC, UPEP, urine and serum immunofixation |
| Monoclonal free kappa or lambda on urine IFE | Bence Jones protein present | Full monoclonal gammopathy workup |
| Negative urine study with abnormal serum FLC | Monoclonal light chains may still be present in blood | Serum-based assessment and clinical context |
A kappa-to-lambda ratio in serum is well established for monoclonal gammopathy assessment. Urine kappa/lambda ratios are more variable and are not interpreted using the same universal decision limits as serum. Never apply a serum FLC ratio reference range to a urine result.
Why a high urine light chain is not always myeloma
Several non-myeloma situations can raise urinary light chains. Reduced kidney function may alter filtration and tubular reabsorption, while inflammation or infection can increase polyclonal immunoglobulin production. Tubular kidney disorders can also allow more normally produced light chains to escape into urine. In these settings both kappa and lambda may rise rather than showing one sharply dominant monoclonal species.
The laboratory method matters as well. Free light chains exist as monomers, dimers, fragments, and larger complexes, and different antisera do not recognize every molecular form identically. Urine concentration varies substantially with hydration, making a concentration in mg/L difficult to compare across samples unless the collection and reporting method are consistent. These analytical and biological issues are why immunofixation, electrophoresis, and serum FLC testing remain central when the clinical question is monoclonality rather than simple protein quantity. If a report is unexpectedly abnormal, repeating the same method under comparable conditions may be more informative than comparing it with a value from a different laboratory platform.
Numerical urine light-chain values should always be read with the laboratory method, units, and specimen type. A concentration from a random urine sample is not directly interchangeable with a 24-hour excretion amount, and laboratories may use different assays. Trends are most reliable when the same method and comparable collection conditions are used over time.
Free light chains and kidney risk
Monoclonal free light chains can injure the kidneys in several ways. The most urgent myeloma-related pattern is light-chain cast nephropathy, in which very high filtered FLC levels interact with proteins in the distal nephron and form obstructing, inflammatory casts. Kidney function can deteriorate rapidly.
Other monoclonal protein–related kidney diseases include AL amyloidosis, light-chain deposition disease, and a range of lesions grouped under monoclonal gammopathy of renal significance. These disorders can produce very different urine patterns. Cast nephropathy often causes substantial non-albumin proteinuria, while AL amyloidosis commonly causes heavy albuminuria because the glomeruli are affected.
The International Myeloma Working Group recommends measuring serum FLCs together with creatinine, estimated GFR, and 24-hour urine total protein, electrophoresis, and immunofixation in myeloma patients with renal impairment. In the right clinical setting, a very high involved serum FLC level increases concern for cast nephropathy. If serum involved FLC is below about 500 mg/L or the urine pattern is dominated by albumin, kidney biopsy may be needed to define the cause rather than assuming cast nephropathy.
Why kidney injury can change the urine result
Kidney disease does not simply make all urine light chains higher. Severe loss of filtration can reduce how much FLC reaches the urine even while blood concentrations rise dramatically. Tubular injury also changes reabsorption. As a result, urinary excretion may fall or behave unpredictably in advanced renal dysfunction.
This is a major reason serum FLC measurements are preferred for rapid assessment of light-chain burden. Urine results remain clinically useful, but they must be interpreted as the product of both plasma-cell production and kidney handling.
New or rapidly worsening kidney dysfunction in someone with known or suspected myeloma is a time-sensitive problem. Early reduction of the monoclonal light-chain burden can improve the chance of renal recovery, so treatment decisions should not wait for repeated outpatient urine tests when the clinical picture is urgent.
Urine versus serum free light chain testing
Modern practice has shifted strongly toward serum testing for screening and monitoring because serum FLC assays are more sensitive and easier to standardize than urine measurements. A serum panel can detect abnormal kappa/lambda production even before enough light chain escapes into urine to be easily detected.
For screening most monoclonal gammopathies, clinicians commonly combine serum protein electrophoresis, serum immunofixation, and serum free light chains. Urine remains particularly important when AL amyloidosis is suspected and in selected myeloma response or renal assessments.
| Test | Main strength | Main limitation |
|---|---|---|
| Serum free light chains | Sensitive quantification of kappa, lambda, and ratio | Kidney function and assay method affect interpretation |
| UPEP | Shows and quantifies urinary monoclonal protein in timed urine | Less sensitive and collection-dependent |
| Urine immunofixation | Confirms monoclonal light-chain type | Usually qualitative and may need concentrated urine |
| Quantitative urine FLC | Measures urinary kappa and lambda concentrations | Strongly affected by urine concentration and renal handling |
One practical consequence is that urine and serum tests can disagree without either being technically wrong. A patient may have a clearly abnormal serum FLC level and ratio while urine immunofixation is negative because renal reabsorption limits urinary excretion. Conversely, a urinary monoclonal band can remain useful for characterizing a disease that historically produced measurable Bence Jones protein.
What happens after an abnormal result
An abnormal urine free light chain result should be interpreted as part of a monoclonal gammopathy workup. The clinician usually confirms whether the pattern is monoclonal and assesses whether there is organ damage.
Follow-up may include serum free light chains and ratio, SPEP, serum and urine immunofixation, CBC, calcium, creatinine, quantitative urine protein, and imaging for bone disease. If these tests support a plasma-cell neoplasm, bone marrow biopsy and cytogenetic or molecular studies help establish the diagnosis and risk profile.
A monoclonal protein does not automatically mean active multiple myeloma. MGUS is common with increasing age and may require monitoring rather than treatment. Smoldering myeloma also has no myeloma-defining organ damage but carries a higher progression risk. Active myeloma is diagnosed using bone marrow or plasmacytoma evidence plus myeloma-defining clinical or biomarker criteria.
Seek prompt medical evaluation for markedly decreased urine output, rapidly worsening swelling, severe weakness, confusion, dehydration, new severe bone pain, or known monoclonal gammopathy with a sudden rise in creatinine. These features may indicate kidney injury, high calcium, fracture, infection, or another complication requiring urgent treatment.
The most useful question is not simply “Are my urine light chains high?” but “Is there a confirmed monoclonal light chain, how much disease is present in serum and urine, and is it causing organ damage?” That framework prevents both overdiagnosis from an isolated abnormal number and delay when a true plasma-cell disorder is damaging the kidneys.
References
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management 2024 (Review)
- Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group 2023 (Guideline)
- Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies 2024 (Review)
- Urine immunofixation electrophoresis and serum free light chain analyses benefit diagnosis of multiple myeloma in orthopedic patients with normal serum total proteins, creatinine, calcium, and hemoglobin 2024
- Urine Protein Immunofixation Electrophoresis: Free Light Chain Urine Immunofixation Electrophoresis Is More Sensitive than Conventional Assays for Detecting Monoclonal Light Chains and Could Serve as a Marker of Minimal Residual Disease. 2023
- The choice of serum-free light chain analysis method could potentially have clinical consequences for myeloma patients 2024
Disclaimer
This article is for general education and does not replace evaluation by a hematologist, nephrologist, or other qualified clinician. Urine free light chain results depend on assay method, collection type, and kidney function, and they cannot diagnose multiple myeloma by themselves. Rapidly worsening kidney function in someone with a monoclonal gammopathy requires prompt medical assessment.
